Alume Biosciences reports positive topline results from three pivotal trials of **Bevonescein**, its potential first-in-class drug for surgical nerve visualization. The findings advance the company toward a **New Drug Application (NDA) submission** with the **U.S. FDA**, targeting the second half of 2026. Bevonescein aims to improve intraoperative nerve identification during surgeries.
Alume names **Daniel Bradbury** as its executive chair. The company also welcomes **Dr. Geoffrey Ling** and **Dr. Craig Venter** to its Strategic Advisory Board, aiming to advance fluorescence technology from Nobel-winning research into **Precision Surgery®** applications. The appointments align with Alume’s focus on translating scientific breakthroughs into surgical precision tools.
Alume Biosciences names Kaveri Parker as Chief Business Officer. The late-clinical stage biotech firm specializes in nerve-illuminating technology aimed at improving surgical precision. Parker joins to advance commercialization efforts for the company’s surgical innovation.
Alume Biosciences names Rick Gonzalez as Chief Commercial Officer. Gonzalez brings over three decades of commercial leadership experience to the biotech company. His appointment aims to accelerate Alume’s growth in developing and commercializing its therapeutic platforms.
